In humans, ADRB3 deficiency has been associated with an increased risk of developing cardiovascular diseases and obesity [19]. Therefore, like POMC and NPY, altering the methylation status of ADRB3 by therapeutic agents is another excellent candidate for continued research in the efforts against obesity. This evidence concerns the gene ADRB3 and Obesity.